five star infusion

Are you POSITIVE FOR COVID and want Monoclonal Antibody treatment?

Five Star Infusion

Five Star Infusion is now administering COVID treatment for patients that qualify & have mild to moderate symptoms.  At Five Star Infusion we are dedicated to increasing access to this life saving treatment and eliminating any barriers to treatment.  We currently provide in home treatments for seniors & veterans that can not make it to the treatment site.

If you do not have transportation and can not afford a ride to the site call us at 469-492-2534 and we will arrange transportation for you.  We are committed to serving the underserved and feel everyone should have equal access to this treatment.


If you’ve tested positive for COVID-19, one of the first questions you may have is, What can I do to reduce the risk of getting sicker? The good news is, there are treatments that may reduce that risk. Depending on your age, health history, and how long you’ve had symptoms of COVID-19, you may qualify for a promising form of treatment for the disease. It’s called monoclonal antibody (mAb) treatment.  The key is early treatment, we recommend everyone who qualifies for treatment, symptomatic, and, has a positive COVID test be treated as soon as possible. 

Evidence suggests that mAb treatment can reduce the amount of the SARS-CoV-2 virus (the virus that causes COVID-19) in a person’s system. This amount is known as viral load. Having a lower viral load means you may have milder symptoms thereby decreasing the likelihood of you needing to stay in the hospital.

mAb treatment may help people who:

Call Five Star Infusion at 469-492-2534 and our pharmacist or doctor can determine if you qualify for treatment. 

How much does it cost? 

If you do not have insurance you can still receive the treatment at no cost to you.  Call us now for more details at 469-492-2534 at receive the treatment the same day. 

There are 3 Monoclonal Antibodies approved to treat mild to moderate COVID


Emergency Use Authorization (EUA)

REGEN-COV is an investigational medicine that may benefit certain people with COVID-19 and may help prevent certain people who have been exposed to someone who is infected with SARS-CoV-2 from getting SARS-CoV-2 infection, or may prevent certain people who are at high risk of exposure to someone who is infected with SARS-CoV-2 from getting SARS-CoV-2 infection.

It is still being studied and there is limited information known about its safety and effectiveness. The U.S. Food and Drug Administration (FDA) has authorized the emergency use of REGEN-COV for the treatment of COVID-19 and the post-exposure prevention of COVID-19 under an EUA.


Bamlanivimab and etesevimab :

Bamlanivimab and etesevimab are investigational medicines used together in adults and adolescents (12 years of age or older who weigh at least 88 pounds [40 kg]) who are at high risk for developing severe COVID-19, including hospitalization or death for:

  • treatment of mild to moderate symptoms of COVID-19, OR
  • post-exposure prophylaxis for prevention of COVID-19 in persons who are:
    • not fully vaccinated against COVID-19 (individuals are considered to be fully vaccinated 2 weeks after their second dose in a 2-dose series [such as the Pfizer or Moderna vaccines], or 2 weeks after a single-dose vaccine [such as Johnson & Johnson’s Janssen vaccine]), or
    • are not expected to build up enough of an immune response to the complete COVID-19 vaccination (for example, someone with immunocompromising conditions, including someone who is taking immunosuppressive medications), and
      • have been exposed to someone who is infected with SARS-CoV-2. Close contact with someone who is infected with SARS-CoV-2 is defined as being within 6 feet for a total of 15 minutes or more, providing care at home to someone who is sick, having direct physical contact with the person (hugging or kissing, for example), sharing eating or drinking utensils, or being exposed to respiratory droplets from an infected person (sneezing or coughing, for example). For additional details, go hereor
      • someone who is at high risk of being exposed to someone who is infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (for example, nursing homes, prisons).
    • Bamlanivimab and etesevimab are not authorized for pre-exposure prophylaxis for prevention of COVID-19

Bamlanivimab and etesevimab have not been approved, but have been authorized for emergency use by the FDA. Bamlanivimab and etesevimab are authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of bamlanivimab and etesevimab under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

For information on the authorized use of bamlanivimab and etesevimab, and mandatory requirements under the Emergency Use Authorization, please review the Fact Sheet for Patients, Parents and Caregivers (English) or Fact Sheet for Patients, Parents and Caregivers (Spanish).


Sotrovimab is an investigational medicine used to treat mild-to-moderate symptoms of COVID-19 in adults and children (12 years of age and older weighing at least 88 pounds [40 kg]) with positive results of direct SARS-CoV-2 viral testing, 

and who are at high risk of progression to severe COVID-19, including hospitalization or death. Sotrovimab is investigational because it is still being studied. There is limited information about the safety and effectiveness of using sotrovimab to treat people with mild-to-moderate COVID-19.